首页> 外文期刊>Inorganica Chimica Acta >Complexes with the fac-{M(CO)(3)}(+) (M=Tc-99m, Re) moiety and long alkyl chain ligands as Lipiodol surrogates
【24h】

Complexes with the fac-{M(CO)(3)}(+) (M=Tc-99m, Re) moiety and long alkyl chain ligands as Lipiodol surrogates

机译:具有fac- {M(CO)(3)}(+)(M = Tc-99m,Re)部分和长烷基链配体的复合物,如Lipiodol替代物

获取原文
获取原文并翻译 | 示例
           

摘要

Accumulation of radiopharmaceuticals in the liver is frequently observed and represents in general a limiting factor when developing novel labeled compounds for any purpose in nuclear medicine. Aiming at the treatment of liver cancer with radiopharmaceuticals, such accumulation is desired but the compounds have to remain in the liver over an extended time period rather than being washed out or redistributed over time in the whole body. Lipiodol is known to remain in the liver and we present here a study for the preparation of Re-186 and (99-Tm)labeled Lipiodol surrogates expected to behave similarly. We have synthesized two bidentate and two tridentate ligands conjugated to a pendant C18 chain as well as their corresponding fac-[Re(CO)(3)](+) and fac-[Tc(CO)(3)](+) complexes. Three of the rhenium complexes have been structurally characterized. Labelling with [Re-186(OH2)(3)(CO)(3)](+) and [Tc-99m(OH2)(3)(CO)(3)](+), respectively, gave yields in the range of 90%. The complexes could be extracted into Lipiodol due to their high lipophilicity and close structural relationship with the major components of Lipiodol. The complexes are stable in water and in Lipiodol for more than 24 h. These Lipiodol surrogates present new low-valent technetium and rhenium complexes for applications in liver cancer imaging and therapy. (c) 2006 Elsevier B.V. All rights reserved.
机译:在开发用于核医学中任何目的的新型标记化合物时,经常会观察到放射性药物在肝脏中的积累,通常代表着一个限制因素。旨在用放射性药物治疗肝癌,这种积累是期望的,但是化合物必须在延长的时间内保留在肝脏中,而不是随着时间的流逝而在整个体内重新分布或重新分布。已知Lipiodol保留在肝脏中,我们在这里进行一项研究,以制备预期具有相似行为的Re-186和(99-Tm)标记的Lipiodol替代物。我们合成了两个C齿和两个三齿配体,它们与一条C18侧链结合,以及它们相应的fac- [Re(CO)(3)](+)和fac- [Tc(CO)(3)](+)配合物。三种complex配合物已进行了结构表征。分别用[Re-186(OH2)(3)(CO)(3)](+)和[Tc-99m(OH2)(3)(CO)(3)](+)标记,范围为90%。由于其高亲脂性和与脂质碘油主要成分的紧密结构关系,可以将其提取到脂质碘油中。配合物在水中和在Lipiodol中稳定超过24小时。这些Lipiodol替代物提供了新的低价tech和rh配合物,可用于肝癌成像和治疗。 (c)2006 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号